Evidence map›Paper›PMID 37050906›Full record

ArticleFrontiers in pharmacology2023

Differential effects of ELX/TEZ/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G.

Sophia T Pallenberg, Inka Held, Christian Dopfer, Rebecca Minso, Manuel M Nietert, Gesine Hansen, Burkhard Tümmler, Anna-Maria Dittrich

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Sophia T PallenbergDepartment of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Inka HeldKinderärzte Friesenweg-CF-Zentrum Altona (Ambulanz), Hamburg, Germany.
Christian DopferDepartment of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Rebecca MinsoDepartment of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Manuel M NietertDepartment of Medical Bioinformatics, University Medical Center Göttingen, Göttingen, Germany.
Gesine HansenDepartment of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Burkhard TümmlerDepartment of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Anna-Maria DittrichDepartment of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
German Center for Lung Research · DEMedizinische Hochschule Hannover · DEAsklepios Klinik Altona · DEUniversitätsmedizin Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

c.165-2A>GCFTR rare mutationscystic fibrosis transmembrane conductance regulator (CFTR)elexacaftor/tezacaftor/ivacaftorexon 3

Identifiers

PMID37050906
PMCPMC10083416
OpenAlexW4360982930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.